In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target ...
Pharmaceutical Technology on MSN6d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mAdditionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...
Parvinder Singh transformed Ranbaxy into a global pharmaceutical powerhouse, but the empire he built crumbled under his sons’ ...
Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...
While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...
Magnificent Seven stocks. Big Tech's runaway growth created gains, but headwinds are forming and some observers doubt the Mag ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback